Influenza vaccines

Vaccine

Volumn 27, Issue SUPPL. 4, 2009, Pages

  Ellebedy, A H ^a   Webby, R J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Hemagglutinin; Immunogenicity; Influenza

Indexed keywords

ADJUVANT; INFLUENZA VACCINE;

ARTICLE; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; INFLUENZA A; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A; NONHUMAN; PRIORITY JOURNAL; VIRUS INACTIVATION; VIRUS TRANSMISSION;

EID: 74749098765     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.038     Document Type: Article

References (54)

1. Krug RM. The potential use of influenza virus as an agent for bioterrorism. Antiviral Res 2003;57(1-2):147-50.
2. Potter CW. A history of influenza. J Appl Microbiol 2001;91(4):572-9.
3. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000;69:531-69.
4. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2000;2:CD001269.
5. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005;366(October (9492)):1165-74.
6. Gross PA, Ennis FA, Gaerlan PF, Denson LJ, Denning CR, Schiffman D. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis 1977;136(5):623-32.
7. Wright PF, Thompson J, Vaughn WK, Folland DS, Sell SH, Karzon DT. Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis 1977;Suppl. 136:S731-41.
8. Mostow SR, Schoenbaum SC, Dowdle WR, Coleman MT, Kaye HS. Studies with inactivated influenza vaccines purified by zonal centrifugation. 1. Adverse reactions and serological responses. Bull World Health Org 1969;41(3):525-30.
9. Peck Jr FB. Purified influenza virus vaccine. A study of viral reactivity and antigenicity. JAMA 1968;206(December (10)):2277-82.
10. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006;367(May (9523)):1657-64.
11. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354(Match (13)):1343-51.
12. Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 2006;43(November (9)):1135-42.
13. Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003;21(April (15)):1687-93.
14. Fedson DS. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Public Health Policy 2005;26(1):4-29.
15. Fedson DS. Vaccine development for an imminent pandemic: why we should worry, what we must do. Hum Vaccine 2006;2(January-February (1)):38-42.
16. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003;21(May (16)):1776-9.
17. Wood JM, Robertson JS. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2004;2(10):842-7.
18. Maassab HF, Heilman CA, Herlocher ML. Cold-adapted influenza viruses for use as live vaccines for man. Adv Biotechnol Processes 1990;14:203-42.
19. Wareing MD, Tannock GA. Live attenuated vaccines against influenza; an historical review. Vaccine 2001;19(May (25-26)):3320-30.
20. Murphy BR, Park EJ, Gottlieb P, Subbarao K. An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters. Vaccine 1997;15(August-September (12-13)):1372-8.
21. Parkin NT, Chiu P, Coelingh K. Genetically engineered live attenuated influenza A virus vaccine candidates. J Virol 1997;71(4):2772-8.
22. Talon J, Salvatore M, O'Neill RE, Nakaya Y, Zheng H, Muster T, et al. Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc Natl Acad Sci USA 2000;97(April (8)):4309-14.
23. Watanabe T, Watanabe S, Ito H, Kida H, Kawaoka Y, Influenza. A virus can undergo multiple cycles of replication without M2 ion channel activity. J Virol 2001;75(12):5656-62.
24. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerg Infect Dis 2006;12(1):48-54.
25. Edwards KM, Dupont WD, Westrich MK, Plummer Jr WD, Palmer PS, Wright PF. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994;169(1):68-76.
26. Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006;355(December (24)):2513-22.
27. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Avian flu: influenza virus receptors in the human airway. Nature 2006;440(March (7083)):435-6.
28. van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, Osterhaus AD, et al. H5N1 virus attachment to lower respiratory tract. Science 2006;312(April (5772)):399.
29. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 2000;97(May (11)):6108-13.
30. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 1999;96(August (16)):9345-50.
31. Subbarao K, Chen H, Swayne D, Mingay L, Fodor E, Brownlee G, et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003;305(January (1)):192-200.
32. Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, Govorkova EA, et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 2004;363(April (9415)):1099-103.
33. Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol 2004;82(5):497-505.
34. Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008;197(March (5)):667-75.
35. Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 2006;194(July (2)):159-67.
36. Lipatov AS, Hoffmann E, Salomon R, Yen HL, Webster RG. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis 2006;194(October (8)):1040-3.
37. Stephenson I, Nicholson KG, Gluck R, Mischler R, Newman RW, Palache AM, et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003;362(December (9400)):1959-66.
38. Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, Pistoor FH, et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 2008;3(1):e1401.
39. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001;357(June (9272)):1937-43.
40. Frey S, Poland G, Percell S, Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a nonadjuvanted influenza vaccine in non-elderly adults. Vaccine 2003;21(October (27-30)):4234-7.
41. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009;28(7):563-71.
42. Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, Subbarao K, et al. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 2002;8(8):796-801.
43. Kodihalli S, Kobasa DL, Webster RG. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine 2000;18(May (23)):2592-9.
44. Qiu M, Fang F, Chen Y, Wang H, Chen Q, Chang H, et al. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressingDNAin BALB/c mice. Biochem Biophys ResCommun 2006;343(May (4)):1124-31.
45. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006;24(May (21)):4475-81.
46. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009;4(2):e4384.
47. Malherbe L, Mark L, Fazilleau N, McHeyzer-Williams LJ, McHeyzer-Williams MG. Vaccine adjuvants alter TCR-based selection thresholds. Immunity 2008;28(5):698-709.
48. Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomainbased influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009;8(4):499-508.
49. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004;22(August (23-24)):2993-3003.
50. Jegerlehner A, Schmitz N, Storni T, Bachmann MF, Influenza. A vaccine based on the extracellular domain of M2: weak protection mediated via antibodydependent NK cell activity. J Immunol 2004;172(May (9)):5598-605.
51. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ. Protection of mice against influenza A virus challenge by vaccination with baculovirusexpressed M2 protein. Vaccine 1995;13(15):1399-402.
52. Chen Y, Qin K, Wu WL, Li G, Zhang J, Du H, et al. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J Infect Dis 2009;199(January (1)):49-58.
53. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L, et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005;23(November (46-47)):5404-10.
54. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009;324(April (5924)):246-51.